Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study aims to explore whether acute tryptophan depletion can affect the emotion and interference processing whether this effect is moderated by the TPH2 genotype
Based on previous studies suggesting that serotonin, a neurotransmitter, is associated with social & emotional behavior, including emotional reactivity and emotion regulation, the present study aims to explore effects of acute tryptophan depletion (ATD) on emotion processing and emotional interference processing within a randomized double-blind, with-subject, placebo-controlled pharmaco-fMRI experiment. To further examine the potential moderating effects of the genetic makeup of the serotonin system the present study will include a pharmacogenetics imaging approach. Given that TPH2 is the key regulator of the serotonergic signaling pathway, we therefore assessed whether such the effects of tryptophan depletion vary according to the TPH2 genotype. To this end, healthy male TPH2-GG or TPH2-TT carriers will be recruited and will receive ATD (100g) and placebo (102.3g) in a within subject design. To control for potential effects of pre-medication personality traits as well as effects of medicines on mood, subjects will be administered pre-treatment assessing relevant personality traits and post-treatment assessments of mood.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| male TPH2-GG carriers with ATD then placebo group | Experimental | male TPH2-GG carriers will first receive ATD, then will receive placebo at least 5 weeks later. |
|
| male TPH2-GG carriers with placebo then ATD group | Experimental | male TPH2-GG carriers will first receive placebo, then will receive ATD at least 5 weeks later. |
|
| male TPH2-TTcarriers with ATD then placebo group | Experimental | male TPH2-TT carriers will first receive ATD, then will receive placebo at least 5 weeks later. |
|
| male TPH2-TTcarriers with placebo then ATD group | Experimental | male TPH2-TT carriers will first receive placebo,then will receive ATD at least 5 weeks later. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ATD treatment | Drug | oral administration of ATD (100g)(Acute Tryptophan Depletion) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Neural processing during emotion processing as assessed via fMRI | Subjects will undergo a validated emotional face paradigm. To assess genotype x ATD interaction effects on neural emotional reactivity effects of ATD depletion on the corresponding neural activity will be compared between the TPH2 genotype groups. | 5-6h after administration of ATD, or placebo |
| Neural processing during interference processing as assessed via fMRI | Subjects will undergo a validated cognitive-emotional interference paradigm. To assess genotype x ATD interaction effects on neural interference control effects of ATD depletion on the corresponding neural activity will be compared between the TPH2 genotype groups. | 5-6h after administration of ATD, or placebo |
| Neural processing during the resting state as assessed via fMRI | Subjects will undergo a validated resting state assessment. To assess genotype x ATD interaction effects on intrinsic brain activity in the emotion and interreference related neural networks effects of ATD depletion on the corresponding neural activity will be compared between the TPH2 genotype groups. | 5-6h after administration of ATD, or placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Behavioral interference performance | Subjects will undergo a emotion-cognition interference paradigm. To assess genotype x ATD interaction effects on behavioral indices of interference (congruent vs incongruent trials) behavioral performance (accuracy/reaction time) effects of ATD depletion on the corresponding behavioral indices will be compared between the TPH2 genotype groups. | 5-6h after administration of ATD, or placebo |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Benjamin Becker, Dr. | Contact | 86-28-61830988 | ben_becker@gmx.de |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| School of Life Science and Technology | Recruiting | Chengdu | Sichuan | 611731 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| placebo treatment | Drug | oral administration of placebo (102.3g) |
|